* Pozen to get $10 mln payment from AstraZeneca
* Shares rise 11 pct
Pozen Inc said U.S. health regulators have accepted a marketing application for its experimental pain drug Vimovo, triggering a $10 million milestone payment from AstraZeneca to Pozen.
The drug is a combination of AstraZeneca's top-selling ulcer drug Nexium and the older generic anti-inflammatory drug naproxen.
Pozen shares were up 9 percent to $7.03 in morning trade Monday on Nasdaq. They touched a high of $7.18 in early trade. (Reporting by Shailesh Kuber in Bangalore; Editing by Gopakumar Warrier)